Overview

Febuxostat for Tumor Lysis Syndrome Prevention in Hematological Malignancies of Paediatric Patients and Adults

Status:
Terminated
Trial end date:
2018-07-25
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the exposure of febuxostat in pediatric patients (≥6<18 years of age) and in adults suffering from hematological malignancies at intermediate to high risk of TLS and to compare the effect in terms of serum uric acid levels.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Menarini Group
Treatments:
Febuxostat